The Debt Crosses $40 Trillion Any Day Now. The Escape Plan Is 80 Years Old.
America's debt hits $40 trillion any day now. Interest alone runs $3.8 billion a day. The last time the hole...
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
America's debt hits $40 trillion any day now. Interest alone runs $3.8 billion a day. The last time the hole...
The standing BullScope yardsticks for Deere &, computed from official filings and refreshed with each new edition.
Deere's stock is priced for a margin peak the filings say hasn't arrived yet. That gap is the whole story....
Adobe spent most of the 2010s convincing skeptical investors that giving up one-time software sales for monthly subscriptions was a...
NVIDIA has committed $1.5 billion to SB Energy and secured exclusive rights to 4.25 IT-GW of initial AI compute capacity...
The standing BullScope yardsticks for Lowes Companies, computed from official filings and refreshed with each new edition.
Six years ago, Lowe's was the perpetual runner-up, a perfectly decent hardware chain that always seemed to be one step...
Five years ago, Nike was the envy of every consumer brand on earth. Revenue was climbing, the stock was north...
Target Corporation has entered into a five-year revolving credit facility dated August 14, 2026, with Bank of America as administrative...
The standing BullScope yardsticks for Boeing, computed from official filings and refreshed with each new edition.
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer
© 2026 BullScope. Evidence-first investment research. Not investment advice. · Methodology · Privacy Policy · Terms of Use · Disclaimer